Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.33 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199603 | 0.78 | BRD9 (0.36) | BRD9APPPIK3CBJAK2JAK3 | |
| SCHEMBL12791060 | 0.77 | MAPK1 (0.35) | BRD9APPPIK3CBJAK2JAK3 | |
| SCHEMBL31526759 | 0.77 | ALDH1A1 (0.38) | ALDH1A1DYRK1A | |
| SCHEMBL31721287 | 0.77 | HPGDS (0.36) | ALDH1A1BRD9RPS6KA5RPS6KA4PIK3CB | |
| SCHEMBL2959106 | 0.73 | JAK2 (0.33) | BRD9PIK3CBJAK2JAK3 | |
| SCHEMBL23442190 | 0.72 | CHEK2 (0.45) | ALDH1A1JAK2JAK3USP2CYP1A2 | |
| SCHEMBL17464104 | 0.72 | FGFR1 (0.37) | ALDH1A1RPS6KA5RPS6KA4JAK2JAK3 | |
| SCHEMBL27171964 | 0.72 | ELANE (0.40) | ALDH1A1 | |
| SCHEMBL31721224 | 0.72 | ALOX15 (0.50) | ALDH1A1BRD9PIK3CBJAK2JAK3 | |
| SCHEMBL22835624 | 0.71 | ALDH1A1 (0.42) | ALDH1A1BRD9APPCYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4590396-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841843-A | Compound combined with CRBN protein and degradation agent of CRBN protein | 中国海洋大学 | 2025-04-18 | — | — | CN | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| WO-2024062089-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-101815712-A | Pyrazole compound and as the purposes of RAF inhibitor | PFIZER | 2010-08-25 | — | — | CN | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | ALDH1A1 615/4885BRD9 1086/4885APP 3817/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 1920/4885BRD9 1768/4885APP 295/4885 |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | PDGFRB, PDGFRA, FGFR1 | ALDH1A1 2831/4885BRD9 3122/4885APP 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.